Cellectar biosciences reports financial results for year ended 2024 and provides a corporate update

Achieves alignment with u.s. food and drug administration (fda) on regulatory path for potential accelerated approval of iopofosine i 131 as a treatment for waldenstrÖm macroglobulinemia (wm)
CLRB Ratings Summary
CLRB Quant Ranking